PlasmaPlex™ WGA for Plasma, Serum, Urine

Reproducible Whole Genome Amplification from small amounts of apoptotic DNA
PlasmaPlex™ WGA makes full use of short double-stranded DNA molecules, giving you:

  • Reliable testing of plasma, serum, urine and other clinical samples
  • Selective amplification of circulating tumor and fetal cell DNA fragments
  • The ability to complete epidemiological and pharmacogenomic studies from archived plasma or serum
  • Higher sensitivity for non-invasive diagnostic, prognostic, and predictive tests

Superior Performance

  • Highly representative amplification of entire human or other genomes
  • Effective for double-stranded DNA between 100 – 2,000 bp in length
  • > 90% genotyping success rate from archived serum or plasma
  • >10X more efficient than the most popular method for plasma WGA
  • Faithful representation even for GC-rich sequences

Simple, Rapid Protocol

  • Single-tube, 3-hour, 2-step process
  • No intermediate purifications, no final purification necessary
  • Completely automatable

Important Features of PlasmaPlex Amplified DNA

  • High sequence fidelity
  • Molecular weight same as template DNA
  • Virtually no primer dimers, chimeras, or extraneous DNA background
  • Validated for Q-PCR, oligonucleotide aCGH, genotyping, mutation detection, sequencing, and methylation analysis
  • Used in testing of over 10,000 clinical plasma/serum samples

The PlasmaPlex WGA kits amplify 50 samples for microarray, Q-PCR or NGS analysis. For research use only. Any commercial use requires separate Rubicon license.

The PlasmaPlex WGA Kit is in development. For early access, please contact Rubicon.